
NanoGhost
Biotech company developing a novel drug delivery platform using cell membrane-derived nanoparticles.
About
NanoGhost is a biotechnology company focused on developing a highly selective, first-in-class drug delivery platform. Their platform, 'Nano-Ghosts' (NGs), is derived from the cell membrane of mesenchymal stem cells (MSCs), which naturally target cancer and sites of inflammation. This versatile technology aims to provide highly selective drug targeting for various therapeutic applications.
Similar companies
Clinical-stage biotech developing a monoclonal antibody targeting TSLP for inflammatory diseases.
Shares Life Sciences, Biotech
AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.
Shares Life Sciences, Drug Delivery
Personalized medicine startup focused on accurate cancer treatment through advanced diagnostics and functional drug sensitivity testing.
Shares Life Sciences, HealthTech
AI-powered blood test for early cancer detection and subtyping.
Shares Life Sciences, Biotech
Biotechnology company developing potentially curative cell therapies for cancer patients.
Shares Life Sciences, Biotech
Biotech company developing next-generation immunotherapy agents to unlock the immune system.
Shares Life Sciences, Immunology
Key facts
At-a-glance profile data
- Website
- nano-ghost.com
- Headquarters
- Tel Aviv, Israel
- Founded
- 2019
- Employees
- 11
- Total funding
- -
- Business model
- B2B
Tech stack
Detected on nano-ghost.com, last scanned 19 Oct 2026. Run your own scan
- Analytics
- Google Analytics 4
- Observability
- Sentry
- CMS / Builders
- Ghost
- Hosting
- Google Cloud
- Email provider
- Microsoft 365
Frequently asked
Is NanoGhost trustworthy and reputable?
StartupHub's Data Trust & Reputation score for NanoGhost is 73 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How many employees does NanoGhost have?
NanoGhost has approximately 11 people on record.
